MA40875A - 2,4-DIAMINO-QUINOLEIN SUBSTITUTED AS NEW ANTI-CANCER AGENTS - Google Patents
2,4-DIAMINO-QUINOLEIN SUBSTITUTED AS NEW ANTI-CANCER AGENTSInfo
- Publication number
- MA40875A MA40875A MA040875A MA40875A MA40875A MA 40875 A MA40875 A MA 40875A MA 040875 A MA040875 A MA 040875A MA 40875 A MA40875 A MA 40875A MA 40875 A MA40875 A MA 40875A
- Authority
- MA
- Morocco
- Prior art keywords
- quinolein
- diamino
- substituted
- cancer agents
- new anti
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 150000005010 aminoquinolines Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<!--startfragment-->la présente invention concerne de nouveaux dérivés de 2-amino primaire-4-amino secondaire-quinoléine, leur fabrication, des compositions pharmaceutiques les comprenant et leur utilisation en tant que médicaments. Les composés actifs de la présente invention sont utiles pour le traitement et la prévention de maladies prolifératives néoplasiques et non néoplasiques.<!--endfragment--><! - startfragment -> the present invention relates to novel derivatives of 2-primary amino-4-secondary amino-quinoline, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention are useful for the treatment and prevention of neoplastic and non-neoplastic proliferative diseases. <! - endfragment ->
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073325P | 2014-10-31 | 2014-10-31 | |
| EP15837091.6A EP3212629B1 (en) | 2014-10-31 | 2015-10-26 | Substituted 2,4 diamino-quinoline as new anticancer agents |
| PCT/IB2015/002438 WO2016067112A1 (en) | 2014-10-31 | 2015-10-26 | Substituted 2,4 diamino-quinoline as new anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40875A true MA40875A (en) | 2017-09-06 |
| MA40875B1 MA40875B1 (en) | 2019-01-31 |
Family
ID=55404745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40875A MA40875B1 (en) | 2014-10-31 | 2015-10-26 | Substituted 2,4-diamino-quinoline as new anticancer agents |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US10722505B2 (en) |
| EP (1) | EP3212629B1 (en) |
| JP (1) | JP6588546B2 (en) |
| KR (1) | KR102548547B1 (en) |
| CN (1) | CN107148416B (en) |
| AU (1) | AU2015338844B2 (en) |
| CA (1) | CA2965262C (en) |
| CL (1) | CL2017001073A1 (en) |
| CO (1) | CO2017007325A2 (en) |
| CR (1) | CR20170177A (en) |
| CY (1) | CY1121326T1 (en) |
| DK (1) | DK3212629T3 (en) |
| DO (1) | DOP2017000107A (en) |
| EA (1) | EA037119B1 (en) |
| EC (1) | ECSP17026748A (en) |
| ES (1) | ES2707125T3 (en) |
| GE (1) | GEP20207108B (en) |
| HR (1) | HRP20190107T1 (en) |
| IL (1) | IL251775B (en) |
| LT (1) | LT3212629T (en) |
| MA (1) | MA40875B1 (en) |
| MY (1) | MY193740A (en) |
| NI (1) | NI201700052A (en) |
| PE (1) | PE20191142A1 (en) |
| PH (1) | PH12017500810A1 (en) |
| PL (1) | PL3212629T3 (en) |
| PT (1) | PT3212629T (en) |
| RS (1) | RS58328B1 (en) |
| SG (1) | SG11201703479SA (en) |
| SI (1) | SI3212629T1 (en) |
| TN (1) | TN2017000168A1 (en) |
| TR (1) | TR201900148T4 (en) |
| UA (1) | UA122062C2 (en) |
| WO (1) | WO2016067112A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3452465B1 (en) * | 2016-05-04 | 2020-11-04 | Genoscience Pharma | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases |
| US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
| EP3620164A1 (en) * | 2018-09-05 | 2020-03-11 | Genoscience Pharma SAS | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases |
| AU2019373221B2 (en) | 2018-10-31 | 2022-05-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity |
| UA126619C2 (en) | 2018-10-31 | 2022-11-02 | Гіліад Сайєнсіз, Інк. | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| WO2022033459A1 (en) * | 2020-08-10 | 2022-02-17 | 萧乃文 | Use of double non-oncology drug in preparation of pharmaceutical composition for treating cancers |
| CN112375081B (en) * | 2020-11-23 | 2022-04-12 | 中国医学科学院医药生物技术研究所 | Pyrrole [2,3-d ] pyrimidine derivative with CDK4, 6 or 9 inhibiting activity and preparation method and application thereof |
| CN112876673B (en) * | 2021-01-25 | 2021-12-24 | 山东大学 | A kind of pH-responsive nano-copolymer carrier and its preparation method and application |
| EP4349336A1 (en) | 2022-10-04 | 2024-04-10 | Genoscience Pharma | Combination of substituted 2,4 diamino-quinoline compounds and mek inhibitors for use in the treatment of liver cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8580301A1 (en) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS |
| JP4666256B2 (en) * | 2002-12-10 | 2011-04-06 | 小野薬品工業株式会社 | Nitrogen-containing heterocyclic compound and pharmaceutical use thereof |
| EP1601357A4 (en) * | 2003-03-10 | 2007-10-03 | Schering Corp | Heterocyclic kinase inhibitors: methods of use and synthesis |
| SMT202000244T1 (en) * | 2013-01-15 | 2020-07-08 | Incyte Holdings Corp | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
| EP2976333B1 (en) * | 2013-03-18 | 2018-08-08 | Genoscience Pharma SAS | Quinolines derivatives as novel anticancer agents |
-
2015
- 2015-10-26 MY MYPI2017000628A patent/MY193740A/en unknown
- 2015-10-26 CN CN201580058830.2A patent/CN107148416B/en active Active
- 2015-10-26 PT PT15837091T patent/PT3212629T/en unknown
- 2015-10-26 US US15/543,504 patent/US10722505B2/en active Active
- 2015-10-26 GE GEAP201514494A patent/GEP20207108B/en unknown
- 2015-10-26 EA EA201790949A patent/EA037119B1/en unknown
- 2015-10-26 TN TN2017000168A patent/TN2017000168A1/en unknown
- 2015-10-26 ES ES15837091T patent/ES2707125T3/en active Active
- 2015-10-26 TR TR2019/00148T patent/TR201900148T4/en unknown
- 2015-10-26 UA UAA201705278A patent/UA122062C2/en unknown
- 2015-10-26 JP JP2017522809A patent/JP6588546B2/en active Active
- 2015-10-26 LT LTEP15837091.6T patent/LT3212629T/en unknown
- 2015-10-26 SI SI201530566T patent/SI3212629T1/en unknown
- 2015-10-26 EP EP15837091.6A patent/EP3212629B1/en active Active
- 2015-10-26 DK DK15837091.6T patent/DK3212629T3/en active
- 2015-10-26 WO PCT/IB2015/002438 patent/WO2016067112A1/en active Application Filing
- 2015-10-26 PL PL15837091T patent/PL3212629T3/en unknown
- 2015-10-26 CA CA2965262A patent/CA2965262C/en active Active
- 2015-10-26 CR CR20170177A patent/CR20170177A/en unknown
- 2015-10-26 MA MA40875A patent/MA40875B1/en unknown
- 2015-10-26 RS RS20190110A patent/RS58328B1/en unknown
- 2015-10-26 KR KR1020177013639A patent/KR102548547B1/en active IP Right Grant
- 2015-10-26 SG SG11201703479SA patent/SG11201703479SA/en unknown
- 2015-10-26 AU AU2015338844A patent/AU2015338844B2/en active Active
-
2017
- 2017-04-18 IL IL251775A patent/IL251775B/en active IP Right Grant
- 2017-04-27 DO DO2017000107A patent/DOP2017000107A/en unknown
- 2017-04-28 NI NI201700052A patent/NI201700052A/en unknown
- 2017-04-28 EC ECIEPI201726748A patent/ECSP17026748A/en unknown
- 2017-04-28 CL CL2017001073A patent/CL2017001073A1/en unknown
- 2017-05-02 PH PH12017500810A patent/PH12017500810A1/en unknown
- 2017-07-24 CO CONC2017/0007325A patent/CO2017007325A2/en unknown
- 2017-08-31 PE PE2017001484A patent/PE20191142A1/en unknown
-
2019
- 2019-01-17 HR HRP20190107TT patent/HRP20190107T1/en unknown
- 2019-01-17 CY CY20191100067T patent/CY1121326T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40875A (en) | 2,4-DIAMINO-QUINOLEIN SUBSTITUTED AS NEW ANTI-CANCER AGENTS | |
| EA201792047A1 (en) | NEW CONNECTIONS | |
| TN2019000136A1 (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
| BR112018074185A2 (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| MA42230A (en) | BICYCLIC DERIVATIVES, THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| EA201692301A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| MA47356A1 (en) | Isochromene derivatives useful as inhibitors of phosphoinositide 3-kinases | |
| CY1122441T1 (en) | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATIONS, THEIR PREPARATION AND THERAPEUTIC USE | |
| EA201591541A1 (en) | BETA SECRETASE INHIBITORS 1 (BACE 1) | |
| NZ783506A (en) | Therapeutic compounds | |
| EA202090414A1 (en) | COMPOUNDS AND THEIR APPLICATION | |
| EA202191478A1 (en) | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | |
| JOP20190183B1 (en) | Estrogen receptor modulators | |
| EA201791432A1 (en) | COMPOSITIONS ON THE BASIS OF MONOMETHYLATE PREPARATION | |
| EA202190588A1 (en) | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | |
| MA40366A (en) | TETRAHYDROQUINOLINE DERIVATIVES AS BROMODOMA INHIBITORS | |
| MA44965B1 (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| MA39337B1 (en) | Gpr6 pyrazine modulators | |
| EA201991490A1 (en) | AROMATIC AMIDES OF CARBOXYLIC ACIDS AS BRAKININ B1 RECEPTOR ANTAGONISTS | |
| MA20150350A1 (en) | Derivatives isoxazolidine | |
| EA202191477A1 (en) | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | |
| EA201891680A1 (en) | INDAN DERIVATIVES AS MGLUR7 MODULATORS | |
| WO2017168454A3 (en) | Novel compounds as btk inhibitors | |
| MA39533A1 (en) | Compounds, pharmaceutical composition and their use in the treatment of neurodegenerative diseases | |
| UY37316A (en) | SOLID PHARMACEUTICAL DISPERSION OF A BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITIONS OF THIS, AND USES FOR CANCER TREATMENT |